BioSpero is a biotechnology company developing OrganXpert, a next-generation Organ-on-a-Chip platform that replicates human physiology with precision. The system runs up to 12 chips in parallel, enabling high-throughput and reproducible studies. Its tubing-free microfluidic circulation mimics blood flow, while the cartridge-based design allows quick setup, reduced contamination risk, and scalability. A built-in incubator regulates temperature, CO₂, and humidity for stable long-term culture. OrganXpert supports multi-layered co-cultures and diverse human organ and disease models such as brain, liver, kidney, lung, gut, and cancer. Applications span drug discovery, disease modeling, toxicology, and personalized medicine, as well as cosmetics, nutraceuticals, food safety, and vaccines. Headquartered in Jeju with a Seoul office, BioSpero partners globally with academia and pharma to deliver ethical, cost-effective, and predictive systems that accelerate innovation and reduce animal testing

OrganXpert